ATO-101

· Institut Cancerologie de l'Ouest

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for ATO-101, covering 2025-12-03 to 2025-12-03. Get the full timeline:

Most recent: Clinical Trial Update: Evaluation of Safety, Tolerability and Response of ATO-101™ in Patients With Non-Muscle-Invasive Bladder Cancer (PERSEVERANCE EU) [Phase 1]

See pricing